PurityPaulOR said:For GLP-1 and gluconeogenesis 12 month, here is what the evidence says:The clinical trial data (STE
I respect PurityPaulOR perspective but I think this oversimplifies things a bit. Re: GLP-1 and gluconeogenesis 12 — the subgroup analyses show meaningful heterogeneity.
I am not saying PurityPaulOR wrong entirely — just that the picture is more nuanced than a blanket statement. The STEP data specifically shows dose-dependent variation.